Vedolizumab Archive - medupdate

Livestream
On-Demand
Industrie

Livestream
On-Demand
Industrie

Login my med-update

logout my med-update

Schlagwort

Vedolizumab

CED II

Adipositas / Anti-TNF-Therapie / CED / Clostridioides difficile / Colitis ulcerosa / Diabetes mellitus / Icotrokinra / IL-23-Antikörper / Schwangerschaft / Steroidtherapie / Tofacitinib / Upadacitinib / Vedolizumab

CED II

Divertikulitis / Eisen-Carboxymaltose / Etrasimod / GETAID-Studie / Hypophosphatämie / Koronararterien-Kalk / Mesalazin / Mirikizumab / Obefazimod / Olamkicept / Pankolitis ulcerosa / Proktokolektomie / Tofacitinib / Ustekinumab / Vedolizumab

CED I

Biologikatherapie / Darmerkrankungen / EVOLVE-Studie / IFX-Therapie / Ileozökalresektion / Kono-S-Anastomose / Mikrobiom-Analysen / Morbus Crohn / REACT-2-Studie / Risankizumab / RUN-CD-Studie / SEAVUE-Studie / STARDUST-Studie / Ustekinumab / Vedolizumab

CED II

Divertikulitis / Eisen-Carboxymaltose / Etrasimod / GETAID-Studie / Hypophosphatämie / Koronararterien-Kalk / Mesalazin / Mirikizumab / Obefazimod / Olamkicept / Pankolitis ulcerosa / Proktokolektomie / Tofacitinib / Ustekinumab / Vedolizumab

CED I

Biologikatherapie / Darmerkrankungen / EVOLVE-Studie / IFX-Therapie / Ileozökalresektion / Kono-S-Anastomose / Mikrobiom-Analysen / Morbus Crohn / REACT-2-Studie / Risankizumab / RUN-CD-Studie / SEAVUE-Studie / STARDUST-Studie / Ustekinumab / Vedolizumab

med update GmbH
Hagenauer Straße 53
65203 Wiesbaden

AGB Impressum Datenschutz Cookie Einstellungen